SCHEMBL7986916

SCHEMBL7986916

CCOC(=O)C([O])O

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8717671 0.80
SCHEMBL1249258 0.79 ALDH1A1 (0.53)
SCHEMBL112149 0.79 ALDH1A1 (0.53)
SCHEMBL112148 0.79 ALDH1A1 (0.53)
SCHEMBL903490 0.79
SCHEMBL14763884 0.79 ALDH1A1 (0.53)
SCHEMBL18213891 0.79 ALDH1A1 (0.53)
SCHEMBL805601 0.79 ALDH1A1 (0.53)
SCHEMBL8645598 0.79 ALDH1A1 (0.53)
SCHEMBL28012631 0.79 ALDH1A1 (0.53)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6291530-B1 Aryl-substituted acrylamides with Leukotriene B4 (LTB-4) receptor antagonist activity NOVARTIS AG (CH) 2001-09-18 US disclosed
EP-0942903-A1 ARYL-SUBSTITUTED ACRYLAMIDES WITH LEUKOTRIENE B4 (LTB-4) RECEPTOR ANTAGONIST ACTIVITY Novartis AG (CH) 1999-09-22 EP disclosed
WO-1998013347-A1 ARYL-SUBSTITUTED ACRYLAMIDES WITH LEUKOTRIENE B4 (LTB-4) RECEPTOR ANTAGONIST ACTIVITY NOVARTIS AG (CH) 1998-04-02 WO disclosed